Palo Alto, CA, United States of America

Daniel J Dairaghi

USPTO Granted Patents = 27 

 

Average Co-Inventor Count = 6.9

ph-index = 9

Forward Citations = 344(Granted Patents)


Company Filing History:


Years Active: 2003-2022

Loading Chart...
Loading Chart...
27 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Daniel J. Dairaghi

Introduction

Daniel J. Dairaghi is a prominent inventor based in Palo Alto, California, with an impressive portfolio of 27 patents. His work primarily focuses on the development of novel compounds for pharmaceutical applications, particularly targeting inflammatory diseases. Dairaghi’s contributions play a significant role in advancing medical research and treatment options.

Latest Patents

Among Dairaghi's latest innovations are the patents for heteroaryl sulfonamides and CCR6 compounds. The heteroaryl sulfonamides are designed as potent antagonists of the CCR2 receptor. Animal testing has demonstrated that these compounds are effective in treating inflammation, which is a hallmark disease associated with CCR2. These compounds mainly consist of aryl sulfonamide derivatives, making them valuable for pharmaceutical compositions and methods aimed at treating CCR2-mediated diseases. Furthermore, the CCR6 compounds are beneficial in addressing diseases modulated through the CCR6 receptor, further exemplifying Dairaghi’s focus on inflammatory conditions.

Career Highlights

Throughout his career, Daniel J. Dairaghi has made significant strides in pharmaceutical innovation. He has worked with various reputable companies, including ChemoCentryx, Inc. and Schering Corporation. His experience in these organizations has allowed him to develop groundbreaking technologies and treatments that impact public health.

Collaborations

Dairaghi has collaborated with notable peers in the field, including Andrew M.K. Pennell and Thomas J. Schall. Such collaborations foster innovation and allow for the sharing of expertise, ultimately contributing to successful patent applications and the advancement of pharmaceutical sciences.

Conclusion

Daniel J. Dairaghi's dedication to invention and improvement in the pharmaceutical field is evident in his extensive patent portfolio. His latest work on CCR2 and CCR6 receptor antagonists showcases his commitment to addressing critical health issues. As research in this area continues, Dairaghi's contributions are likely to inspire future innovations in the treatment of inflammation and related diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…